Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway

References

• Chung MY, Choi HK, Hwang JT. AMPK activity: a primary target for diabetes prevention with therapeutic phytochemicals. Nutrients. 2021;13(11):4050.
   PubMed Web of Science ®Google Scholar
• Li X, Lu L, Hou W, et al. Epigenetics in the pathogenesis of diabetic nephropathy. Acta Biochim Biophys Sin. 2022;54(2):163–172.
   Google Scholar
• Chen G, Wang H, Zhang W, et al. Dapagliflozin reduces urinary albumin excretion by downregulating the expression of cAMP, MAPK, and cGMP-PKG signaling pathways associated genes. Genet Test Mol Biomarkers. 2021;25(10):627–637.
   PubMed Web of Science ®Google Scholar
• Liu S, Yuan Y, Xue Y, et al. Podocyte injury in diabetic kidney disease: a focus on mitochondrial dysfunction. Front Cell Dev Biol. 2022;10:832887.
   PubMed Web of Science ®Google Scholar
• Zheng W, Guo J, Lu X, et al. cAMP-response element binding protein mediates podocyte injury in diabetic nephropathy by targeting lncRNA DLX6-AS1. Metabolism. 2022;129:155155.
   PubMed Web of Science ®Google Scholar
• Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12(8):1366–1373.
   PubMed Web of Science ®Google Scholar
• Tripathi YB, Yadav D. Diabetic nephropathy: causes and managements. Recent Pat Endocr Metab Immune Drug Discov. 2013;7(1):57–64.
   PubMedGoogle Scholar
• Wheeler DC, Stefansson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Tang G, Li S, Zhang C, et al. Clinical efficacies, underlying mechanisms and molecular targets of chinese medicines for diabetic nephropathy treatment and management. Acta Pharm Sin B. 2021;11(9):2749–2767.
   PubMed Web of Science ®Google Scholar
• Nicholas SB. Novel anti-inflammatory and anti-fibrotic agents for diabetic kidney Disease-From bench to bedside. Adv Chronic Kidney Dis. 2021;28(4):378–390.
   PubMed Web of Science ®Google Scholar
• Deng J, Liu Y, Liu Y, et al. The multiple roles of fibroblast growth factor in diabetic nephropathy. J Inflamm Res. 2021;14:5273–5290.
   PubMed Web of Science ®Google Scholar
• Jha JC, Ho F, Dan C, et al. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci. 2018;132(16):1811–1836.
   PubMed Web of Science ®Google Scholar
• Ostergaard JA, Cooper ME, Jandeleit-Dahm KAM. Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. J Nephrol. 2020;33(5):917–929.
   PubMed Web of Science ®Google Scholar
• Li H, Wang F, Zhang L, et al. Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell Signal. 2011;23(10):1625–1632.
   PubMed Web of Science ®Google Scholar
• Alshehri AS. Kaempferol attenuates diabetic nephropathy in streptozotocin-induced diabetic rats by a hypoglycaemic effect and concomitant activation of the Nrf-2/HO-1/antioxidants axis. Arch Physiol Biochem. 2021:1–14. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Du L, Wang J, Chen Y, et al. Novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy. Cell Biol Toxicol. 2020;36(3):243–260.
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165(4):792–800.
   PubMed Web of Science ®Google Scholar
• Wang L, Hauenstein AV. The NLRP3 inflammasome: mechanism of action, role in disease and therapies. Mol Aspects Med. 2020;76:100889.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Nan J, Mu B, et al. Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. Eur J Med Chem. 2022;232:114194.
   PubMed Web of Science ®Google Scholar
• Gao Y, Ma Y, Xie D, et al. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model. Int Immunopharmacol. 2022;107:108711.
   PubMed Web of Science ®Google Scholar
• Dong W, Jia C, Li J, et al. Fisetin attenuates diabetic nephropathy-induced podocyte injury by inhibiting NLRP3 inflammasome. Front Pharmacol. 2022;13:783706.
   PubMed Web of Science ®Google Scholar
• Zhang K, Lin L, Zhu Y, et al. Saikosaponin d alleviates liver fibrosis by negatively regulating the ROS/NLRP3 inflammasome through activating the ERbeta pathway. Front Pharmacol. 2022;13:894981.
   PubMed Web of Science ®Google Scholar
• Tong L, Zhao Q, Datan E, et al. Triptolide: reflections on two decades of research and prospects for the future. Nat Prod Rep. 2021;38(4):843–860.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhang J, Wang Y, et al. The active compounds and therapeutic target of Tripterygium wilfordii Hook. F. in attenuating proteinuria in diabetic nephropathy: a review. Front Med. 2021;8:747922.
   Web of Science ®Google Scholar
• Ren L, Wan R, Chen Z, et al. Triptolide alleviates podocyte epithelial-mesenchymal transition via kindlin-2 and EMT-Related TGF-beta/smad signaling pathway in diabetic kidney disease. Appl Biochem Biotechnol. 2022;194(2):1000–1012.
   PubMed Web of Science ®Google Scholar
• Han F, Xue M, Chang Y, et al. Erratum: triptolide suppresses glomerular mesangial cell proliferation in diabetic nephropathy is associated with inhibition of PDK1/Akt/mTOR pathway: erratum. Int J Biol Sci. 2020;16(15):3037–3038.
   PubMed Web of Science ®Google Scholar
• Liang X, Chen B, Wang P, et al. Triptolide potentiates the cytoskeleton-stabilizing activity of cyclosporine a in glomerular podocytes via a GSK3beta dependent mechanism. Am J Transl Res. 2020;12(3):800–812.
   PubMed Web of Science ®Google Scholar
• Chen L, Mei G, Jiang C, et al. Carbon monoxide alleviates senescence in diabetic nephropathy by improving autophagy. Cell Prolif. 2021;54(6):e13052.
   PubMed Web of Science ®Google Scholar
• Han F, Xue M, Chang Y, et al. Triptolide suppresses glomerular mesangial cell proliferation in diabetic nephropathy is associated with inhibition of PDK1/Akt/mTOR pathway. Int J Biol Sci. 2017;13(10):1266–1275.
   PubMed Web of Science ®Google Scholar
• Cai T, Ke Q, Fang Y, et al. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1alpha-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis. 2020;11(5):390.
   PubMed Web of Science ®Google Scholar
• Wang Y, Feng F, Sun HW, et al. miR-188-3p abolishes germacrone-mediated podocyte protection in a mouse model of diabetic nephropathy in type I diabetes through triggering mitochondrial injury. Bioengineered. 2022;13(1):774–788.
   PubMed Web of Science ®Google Scholar
• Zheng T, Wang HY, Chen Y, et al. Src activation aggravates podocyte injury in diabetic nephropathy via suppression of FUNDC1-Mediated mitophagy. Front Pharmacol. 2022;13:897046.
   PubMed Web of Science ®Google Scholar
• Shao X, Zhang X, Hu J, et al. Dopamine 1 receptor activation protects mouse diabetic podocytes injury via regulating the PKA/NOX-5/p38 MAPK axis. Exp Cell Res. 2020;388(2):111849.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang Y, He X, et al. Cdk5-mediated phosphorylation of Sirt1 contributes to podocyte mitochondrial dysfunction in diabetic nephropathy. Antioxid Redox Signal. 2021;34(3):171–190.
   PubMed Web of Science ®Google Scholar
• Fan X, Hao Z, Li Z, et al. Inhibition of miR-17 ∼ 92 cluster ameliorates high glucose-induced podocyte damage. Mediators Inflamm. 2020;2020:6126490.
   PubMed Web of Science ®Google Scholar
• Li XY, Wang SS, Han Z, et al. Triptolide restores autophagy to alleviate diabetic renal fibrosis through the miR-141-3p/PTEN/Akt/mTOR pathway. Mol Ther Nucleic Acids. 2017;9:48–56.
   PubMedGoogle Scholar
• Sun J, Zhu H, Wang X, et al. CoQ10 ameliorates mitochondrial dysfunction in diabetic nephropathy through mitophagy. J Endocrinol. 2019. Online ahead of print.
   Web of Science ®Google Scholar
• Wu Q, Li W, Zhao J, et al. Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation. Biomed Pharmacother. 2021;137:111308.
   PubMed Web of Science ®Google Scholar
• Gu J, Shi JZ, Wang YX, et al. LncRNA FAF attenuates hypoxia/ischaemia-induced pyroptosis via the miR-185-5p/PAK2 axis in cardiomyocytes. J Cell Mol Med. 2022;26(10):2895–2907.
   PubMed Web of Science ®Google Scholar
• Jiang W, Xiao T, Han W, et al. Klotho inhibits PKCalpha/p66SHC-mediated podocyte injury in diabetic nephropathy. Mol Cell Endocrinol. 2019;494:110490.
   PubMed Web of Science ®Google Scholar
• Zhu W, Li YY, Zeng HX, et al. Carnosine alleviates podocyte injury in diabetic nephropathy by targeting caspase-1-mediated pyroptosis. Int Immunopharmacol. 2021;101(Pt B):108236.
   PubMedGoogle Scholar
• Li MR, Lei CT, Tang H, et al. MAD2B promotes podocyte injury through regulating numb-dependent notch 1 pathway in diabetic nephropathy. Int J Biol Sci. 2022;18(5):1896–1911.
   PubMed Web of Science ®Google Scholar
• Ucar BI, Ucar G, Saha S, et al. Pharmacological protection against ischemia-reperfusion injury by regulating the Nrf2-Keap1-ARE signaling pathway. Antioxidants. 2021;10(6):823.
   Web of Science ®Google Scholar
• Loboda A, Damulewicz M, Pyza E, et al. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016;73(17):3221–3247.
   PubMed Web of Science ®Google Scholar
• Al Mamun A, Ara Mimi A, Wu Y, et al. Pyroptosis in diabetic nephropathy. Clin Chim Acta. 2021;523:131–143.
   PubMed Web of Science ®Google Scholar
• Tan HB, Zhao Q, Chen L. Penehyclidine hydrochloride suppresses inflammation response and reduces podocyte injury in diabetic nephropathy by targeting fibrinogen-like protein 2. Int Immunopharmacol. 2022;107:108680.
   PubMed Web of Science ®Google Scholar
• Kaewin S, Changsorn K, Sungkaworn T, et al. Fungus-derived 3-hydroxyterphenyllin and candidusin a ameliorate palmitic Acid-Induced human podocyte injury via anti-oxidative and anti-apoptotic mechanisms. Molecules. 2022;27(7):2109.
   PubMed Web of Science ®Google Scholar
• Sun Y, Cui S, Hou Y, et al. The updates of podocyte lipid metabolism in proteinuric kidney disease. Kidney Dis. 2021;7(6):438–451.
   Google Scholar
• Opazo-Rios L, Mas S, Marin-Royo G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21(7):2632.
   Web of Science ®Google Scholar
• Suk Kang J, Son SS, Lee JH, et al. Protective effects of klotho on palmitate-induced podocyte injury in diabetic nephropathy. PLOS One. 2021;16(4):e0250666.
   PubMed Web of Science ®Google Scholar
• Ma R, Liu L, Liu X, et al. Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy. Exp Ther Med. 2013;6(3):649–656.
   PubMed Web of Science ®Google Scholar
• Li Y, Hu Q, Li C, et al. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. J Clin Invest. 2019;129(3):1129–1151.
   PubMed Web of Science ®Google Scholar
• Xue M, Cheng Y, Han F, et al. Triptolide attenuates renal tubular epithelial-mesenchymal transition via the MiR-188-5p-mediated PI3K/AKT pathway in diabetic kidney disease. Int J Biol Sci. 2018;14(11):1545–1557.
   PubMed Web of Science ®Google Scholar
• Pang R, Gu D. Triptolide improves renal injury in diabetic nephropathy rats through TGF-beta1/smads signal pathway. Endocr Metab Immune Disord Drug Targets. 2021;21(10):1905–1911.
   PubMed Web of Science ®Google Scholar
• Xu ZJ, Shu S, Li ZJ, et al. Liuwei dihuang pill treats diabetic nephropathy in rats by inhibiting of TGF-beta/SMADS, MAPK, and NF-kB and upregulating expression of cytoglobin in renal tissues. Medicine. 2017;96(3):e5879.
   PubMed Web of Science ®Google Scholar
• Han F, Wang S, Chang Y, et al. Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA-137/Notch1 pathway. J Cell Physiol. 2018;233(3):2225–2237.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hong Y, Huang H. Triptolide attenuates inflammatory response in membranous glomerulo-nephritis rat via downregulation of NF-kappaB signaling pathway. Kidney Blood Press Res. 2016;41(6):901–910.
   PubMed Web of Science ®Google Scholar
• Sago T, Nakayama R, Okumura T, et al. Metabolism of prostaglandins D2 and F2 alpha in primary cultures of rat hepatocytes. Biochim Biophys Acta. 1986;879(3):330–338.
   PubMedGoogle Scholar
• Lal MA, Young KW, Andag U. Targeting the podocyte to treat glomerular kidney disease. Drug Discov Today. 2015;20(10):1228–1234.
   PubMed Web of Science ®Google Scholar
• Nagata M. Podocyte injury and its consequences. Kidney Int. 2016;89(6):1221–1230.
   PubMed Web of Science ®Google Scholar
• Perez Gutierrez RM, Garcia Campoy AH, Paredes Carrera SP, et al. 3′-O-beta-d-glucopyranosyl-alpha,4,2′,4′,6′-pentahydroxy-dihydrochalcone, from bark of Eysenhardtia polystachya prevents diabetic nephropathy via inhibiting protein glycation in STZ-nicotinamide induced diabetic mice. Molecules. 2019;24(7):1214.
   PubMed Web of Science ®Google Scholar
• Dua K, Sheshala R, Al-Waeli HA, et al. Antimicrobial efficacy of extemporaneously prepared herbal mouthwashes. Recent Pat Drug Deliv Formul. 2015;9(3):257–261.
   PubMedGoogle Scholar
• Gupta G, Chellappan DK, Kikuchi IS, et al. Nephrotoxicity in rats exposed to paracetamol: the protective role of moralbosteroid, a steroidal glycoside. J Environ Pathol Toxicol Oncol. 2017;36(2):113–119.
   PubMed Web of Science ®Google Scholar
• Yang J, Tang X, Ke X, et al. Triptolide suppresses NF-kappaB-Mediated inflammatory responses and activates expression of Nrf2-Mediated antioxidant genes to alleviate caerulein-induced acute pancreatitis. Int J Mol Sci. 2022;23(3):1252.
   Web of Science ®Google Scholar
• Chen Q, Lei YQ, Liu JF, et al. Triptolide improves neurobehavioral functions, inflammation, and oxidative stress in rats under deep hypothermic circulatory arrest. Aging. 2021;13(2):3031–3044.
   PubMedGoogle Scholar
• Dong XG, An ZM, Guo Y, et al. Effect of triptolide on expression of oxidative carbonyl protein in renal cortex of rats with diabetic nephropathy. J Huazhong Univ Sci Technolog Med Sci. 2017;37(1):25–29.
   PubMedGoogle Scholar
• Tang B, Zhu J, Zhang B, et al. Therapeutic potential of triptolide as an anti-Inflammatory agent in dextran sulfate Sodium-Induced murine experimental colitis. Front Immunol. 2020;11:592084.
   PubMed Web of Science ®Google Scholar
• Yu H, Shi L, Zhao S, et al. Triptolide attenuates myocardial ischemia/reperfusion injuries in rats by inducing the activation of Nrf2/HO-1 defense pathway. Cardiovasc Toxicol. 2016;16(4):325–335.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Pan J, Zhou ZL, et al. Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy. Acta Pharmacol Sin. 2021;42(6):954–963.
   PubMed Web of Science ®Google Scholar
• Guo H, Pan C, Chang B, et al. Triptolide improves diabetic nephropathy by regulating Th cell balance and macrophage infiltration in rat models of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2016;124(6):389–398.
   PubMed Web of Science ®Google Scholar
• Wu M, Han W, Song S, et al. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice. Mol Cell Endocrinol. 2018;478:115–125.
   PubMed Web of Science ®Google Scholar
• Du L, Wang J, Chen Y, et al. Correction to: novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy. Cell Biol Toxicol. 2022;38(5):913–914.
   PubMed Web of Science ®Google Scholar
• Yang J, Guo W, Lu M. Confusion about the article: natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-IotaIota. Cancer Lett. 2022;534:115568.
   PubMed Web of Science ®Google Scholar
• He L, Peng X, Liu G, et al. Anti-inflammatory effects of triptolide on IgA nephropathy in rats. Immunopharmacol Immunotoxicol. 2015;37(5):421–427.
   PubMed Web of Science ®Google Scholar
• Shen J, Ma H, Wang C. Triptolide improves myocardial fibrosis in rats through inhibition of nuclear factor kappa B and NLR family pyrin domain containing 3 inflammasome pathway. Korean J Physiol Pharmacol. 2021;25(6):533–543.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li T, Tan P, et al. Kaempferol from penthorum Chinense pursh attenuates hepatic ischemia/reperfusion injury by suppressing oxidative stress and inflammation through activation of the Nrf2/HO-1 signaling pathway. Front Pharmacol. 2022;13:857015.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu L, Meng H, et al. Ferulic acid protects human lens epithelial cells against ionizing radiation-induced oxidative damage by activating Nrf2/HO-1 signal pathway. Oxid Med Cell Longev. 2022;2022:6932188.
   PubMed Web of Science ®Google Scholar
• Sarafidis P, Pella E, Kanbay M, et al. SGLT-2 inhibitors and nephroprotection in patients with diabetic and non-diabetic chronic kidney disease. Curr Med Chem. 2022. Online ahead of print.
   Web of Science ®Google Scholar
• Guo R, Wang P, Zheng X, et al. SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway. Front Pharmacol. 2022;13:897167.
   PubMed Web of Science ®Google Scholar